His primary areas of study are Immunology, Internal medicine, Antiphospholipid syndrome, Antibody and Autoantibody. His Immunology study frequently intersects with other fields, such as Odds ratio. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology and Surgery.
The study incorporates disciplines such as Lupus anticoagulant, Serology, Tertiary referral centre and Genotype in addition to Antiphospholipid syndrome. Tatsuya Atsumi connects Lupus anticoagulant with International congress in his research. Tatsuya Atsumi mostly deals with Beta 2-Glycoprotein I in his studies of Autoantibody.
The scientist’s investigation covers issues in Internal medicine, Immunology, Antiphospholipid syndrome, Antibody and Gastroenterology. The various areas that Tatsuya Atsumi examines in his Internal medicine study include Diabetes mellitus, Endocrinology and Type 2 diabetes. His works in Autoantibody, Autoimmune disease, Lupus erythematosus, Beta 2-Glycoprotein I and Immunopathology are all subjects of inquiry into Immunology.
He combines subjects such as Lupus anticoagulant, Anticardiolipin antibodies and Platelet with his study of Antiphospholipid syndrome. His biological study spans a wide range of topics, including Molecular biology, Antigen and Clinical significance. His Rheumatoid arthritis research integrates issues from Methotrexate, Surgery and Arthritis.
His main research concerns Internal medicine, Endocrinology, Gastroenterology, Type 2 diabetes and Diabetes mellitus. His study on Rheumatoid arthritis, Clinical trial, Glycemic and Insulin is often connected to In patient as part of broader study in Internal medicine. Clinical trial is frequently linked to Antiphospholipid syndrome in his study.
His research on Antiphospholipid syndrome is centered around Antibody and Thrombosis. The Gastroenterology study combines topics in areas such as Anti-neutrophil cytoplasmic antibody and Fatty liver. His studies deal with areas such as Body mass index, Area under the curve and Confidence interval as well as Diabetes mellitus.
Internal medicine, Antiphospholipid syndrome, Clinical trial, Antibody and Diabetes mellitus are his primary areas of study. His work in the fields of Internal medicine, such as Rheumatoid arthritis, overlaps with other areas such as In patient. Antiphospholipid syndrome is a primary field of his research addressed under Thrombosis.
His studies in Clinical trial integrate themes in fields like Adverse effect, Placebo, Tocilizumab and Oncology. His study with Antibody involves better knowledge in Immunology. His Immunology research incorporates elements of Extracellular and Necrotizing Vasculitis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
S. Miyakis;M. D. Lockshin;T. Atsumi;D. W. Branch.
Journal of Thrombosis and Haemostasis (2006)
ANTIPHOSPHOLIPID ANTIBODIES AFFECT TROPHOBLAST GONADOTROPIN SECRETION AND INVASIVENESS BY BINDING DIRECTLY AND THROUGH ADHERED β2-GLYCOPROTEIN I
N Di Simone;P L Meroni;N Del Papa;E Raschi.
Arthritis & Rheumatism (2000)
Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant.
Tatsuya Atsumi;Masahiro Ieko;Maria L. Bertolaccini;Kenji Ichikawa.
Arthritis & Rheumatism (2000)
The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
Olga Amengual;Tatsuya Atsumi;Munther A. Khamashta;Graham R. V. Hughes.
Thrombosis and Haemostasis (1998)
Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases
S Fukaya;S Yasuda;T Hashimoto;K Oku.
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients:
N. M. Shah;M. A. Khamashta;T. Atsumi;G. R. V. Hughes.
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events
Kotaro Otomo;Tatsuya Atsumi;Olga Amengual;Yuichiro Fujieda.
Arthritis & Rheumatism (2012)
Circulating oxidized LDL forms complexes with β2-glycoprotein I implication as an atherogenic autoantigen
Kazuko Kobayashi;Makoto Kishi;Tatsuya Atsumi;Maria L. Bertolaccini.
Journal of Lipid Research (2003)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde;James Cheng-Chung Wei;Maxime Dougados;Philip Mease.
The Lancet (2018)
Enhanced Formation and Disordered Regulation of NETs in Myeloperoxidase-ANCA–Associated Microscopic Polyangiitis
Daigo Nakazawa;Haruki Shida;Utano Tomaru;Masaharu Yoshida.
Journal of The American Society of Nephrology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: